Literature DB >> 2581717

A pharmacokinetic evaluation of IM administration of bleomycin oil suspension.

M Davy, E Paus, G Lehne.   

Abstract

Bleomycin oil suspension was given IM twice daily to four patients, and bleomycin saline solution infused to three patients with cervical carcinoma. The serum levels of bleomycin were followed for 12 h by radioimmunoassay. Both regimens revealed comparable side effects. Only minor responses were seen. Bleomycin oil suspension produced prolonged levels of bleomycin in serum.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2581717     DOI： 10.1007/bf00258133

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  9 in total

1.  Improved therapeutic index of bleomycin when administered by continuous infusion in mice.

Authors:  B I Sikic; J M Collins; E G Mimnaugh; T E Gram
Journal:  Cancer Treat Rep       Date:  1978-12

2.  Delayed-release bleomycin. Comparative pharmacology of bleomycin oil suspension and bleomycin in saline.

Authors:  M L Slevin; V J Harvey; G W Aherne; N K Burton; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  [Studies on absorption, excretion and organ distrubition of bleomycin oil suspension (author's transl)].

Authors:  F Abe; M Tsubosaki; T Tanaka; Y Kato; O Yoshioka
Journal:  Jpn J Antibiot       Date:  1976-09

4.  Radioimmunoassay of bleomycin.

Authors:  A Broughton; J E Strong
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

5.  Pharmacokinetics of bleomycin after im administration in man.

Authors:  M M Oken; S T Crooke; M K Elson; J E Strong; R B Shafer
Journal:  Cancer Treat Rep       Date:  1981 May-Jun

6.  Prospective study of the pulmonary toxicity of continuously infused bleomycin.

Authors:  K R Cooper; W K Hong
Journal:  Cancer Treat Rep       Date:  1981 May-Jun

7.  Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804.

Authors:  S J Ginsberg; S T Crooke; C D Bloomfield; B Peterson; B J Kennedy; J Blom; R R Ellison; T F Pajak; A J Gottlieb
Journal:  Cancer       Date:  1982-04-01       Impact factor: 6.860

8.  Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay.

Authors:  A Broughton; J E Strong; P Y Holoye; C W Bedrossian
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860

9.  Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration.

Authors:  Y M Peng; D S Alberts; H S Chen; N Mason; T E Moon
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.